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Abstract
Plasmodium falciparum serine repeat antigen 5 (SERA5) is a target for both drug and vaccine intervention against malaria.
SERA5 is secreted in the parasitophorous vacuole where it is proteolytically processed before schizont rupture. Among the
processed products is a 50.8-kDa central domain of the protease, which possesses chymotrypsin-like activity and consists of
a 28.9-kDa catalytic domain with a 21.9-kDa N-terminal prodomain, which remain attached together. Because SERA5 has
been implicated in merozoite egress from host erythrocytes, the effect of the prodomain and a heptapeptide derived from
its C-terminus spanning from D
560 to F
566 (DNSDNMF) on parasite growth was studied. When E. coli-expressed prodomain
was incubated with parasite culture, a significant delay in transition from schizont to ring stages was observed up to
nanomolar concentrations. The peptide, DNSDNMF also showed similar effects but at nearly 1000-fold higher
concentrations. The peptide was also found to interact with the catalytic domain. These data demonstrate the crucial
role of SERA5 prodomain for the egress process. Given the inhibitory potential of the prodomain for the parasite, we
suggest that peptidomimetic inhibitors based on SERA5 prodomain sequences can be developed as future therapeutics
against malaria.
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Introduction
Malaria caused by protozoan parasite Plasmodium falciparum is a
global health burden causing enormous suffering and fatality in
the tropical regions of the world [1]. Drug resistance and absence
of a vaccine are the major factors leading to the spread of malaria.
To control P. falciparum malaria, an effective vaccine and new
drugs are urgently needed. One protein, which is important for
both, is the highly expressed blood stage protein known as serine
repeat antigen 5 (SERA5) [2–5]. SERA5 is a member of a large
multigene family with 9 genes in P. falciparum transcribed most
actively at trophozoite and schizont stages, of which eight (SERA1
to 8) are tandemly arranged on chromosome 2 and one (SERA9)
on chromosome 9 [6]. All P. falciparum serine repeat antigens
(SERAs) are transcribed most actively at trophozoite and schizont
stages [7–9] at very different levels in a co-regulated manner [10].
Of these, SERA5 is most highly expressed with approximately
0.5–1.5% of the total mRNA in schizont stages [7] and released
into the culture medium upon schizont rupture [11,12].
To probe the essentiality of SERA genes for parasite blood
stages Miller et al. (2003) and McCoubrie et al. (2007) were
successful in deleting all the P. falciparum SERAs except SERA5
and SERA6 which were refractory to deletion [8,13]. Expression
of SERA5 mRNA increased two-fold in SERA4-null parasites
suggesting a compensatory mechanism in these proteins [13].
Besides, blood stages SERAs have significant expression in other
life cycle stages of the parasite indicating their roles in stages other
than blood stages. Aly and Mutushewski (2005) have demonstrated
that the disruption of the Plasmodium berghei ortholog of P. falciparum
SERA8 led to the blockade of sporozoite release from oocysts [14].
SERA5 is secreted in the parasitophorous vacuole before egress
and undergoes extensive proteolytic processing. It is processed into
a 47-kDa N-terminal domain, a 50-kDa central protease domain,
a 6-kDa fragment and an 18-kDa C-terminal fragment [2,15,16].
Recent reports have demonstrated that SERA5 and other SERA
proteins are processed by PfSUB1, a parasite subtilisin-like
protease [11,17]. The central domains of all SERA proteins show
,20% sequence identity with papain family cysteine proteases
[18]. Phylogenetic analysis has revealed that SERA proteins can
be grouped into two distinct groups, which have either serine or
cysteine as the nucleophile [19]. In P. falciparum, six of the nine
SERAs possess active site serine (SERA1 to 5 and SERA9) and
three possess active site cysteine (SERAs 6 to 8). This non-
conventional substitution of cysteine with a serine raised the
question whether the SERAs with active site serine retained
enzymatic function [8]. Hodder et al. (2003) showed that the 50-
kDa central protease domain of P. falciparum SERA5 possessed
chymotrypsin-like activity in in vitro assays [5].
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merozoite egress [11,17]. Antibodies against the N-terminal 47-
kDa region of the protein inhibited the transition of the parasite
from schizont to ring stage but not from ring to schizont stage and
also caused the agglutination of the released merozoites, suggesting
the involvement of SERA5 in schizont rupture [20]. Sensitivity of
egress and invasion processes to serine and cysteine protease
inhibitors has attracted attention towards the role of proteases in
these processes [11,12,14,16]. Due to the presence of an active
protease domain in SERA5 [5], its indispensability for parasite
survival [8] and indirect evidences implicating SERA5 in
merozoite egress from red blood cells [11,17], the role of its
proteolytic activity and the identity of its physiological substrates
are tempting avenues to be explored.
The central protease domain of SERA5 (T
391 to N
828)i s
composed of a 187-residue prodomain (T
391 to D
577) which
remains attached to the N-terminal of the 251-residue of enzyme
domain (E
578 to N
828) after processing of SERA5 [5]. In case of
zymogens, prodomains are known to have a variety of functions
like prevention of premature activation of enzymes, proper folding
of the protease domain, trafficking of the protease to its final
destination and substrate recognition [21–23]; however, the
physiological significance of the SERA5 prodomain remains
unknown. In this study, we have attempted to explore the
significance of SERA5 prodomain for the protein and role in
merozoite egress.
Results
Cloning, expression and purification of SERA5 catalytic
domain (SERA5 C) and SERA5 prodomain (SERA5 PD)
Hodder et al. (2003) demonstrated weak proteolytic activity in
the 50-kDa central enzyme domain of SERA5 (SERA 5PE).
SERA 5PE consisted of a prodomain and a catalytic domain,
whose boundaries were defined based on sequence alignment with
known papain family cysteine proteases [5]. Figure 1A shows the
schematic representation of SERA 5PE. Figure 1B shows the
sequences corresponding to the prodomain and the catalytic
domain. The complete prodomain polypeptide and a heptapeptide
based on the C-terminal region of the prodomain were used for
egress inhibition studies (Fig. 1A and 1B).
Due to the presence of a serine residue (Ser-596) in place of
catalytic cysteine, weak protease activity and no information on
the physiological substrates, protease activity of SERA5 is a matter
of debate. We were interested in finding out whether the catalytic
domain alone without the prodomain was proteolytically active.
SERA5 C when expressed in E. coli BL21(DE3) cells with N-
terminal hexahistidine tag accumulated mainly in insoluble
fraction and was purified from inclusion bodies by nickel-
nitrilotriacetic acid (Ni-NTA) chromatography (Fig. S1A). Refold-
ed SERA5 C was found to be proteolytically inactive on
fluorogenic substrates, Suc-Leu-Leu-Val-Tyr-AMC and Suc-Ala-
Ala-Pro-Phe-AMC.
Figure 1. Architecture of SERA5 proenzyme. Panel A represents the general architecture of SERA5 proenzyme showing the position of
prodomain and catalytic domain. Panel B shows the sequence of SERA5 proenzyme. Prodomain sequence is shown in bold and underlined. Catalytic
domain sequence is shown in normal case letters. The inhibitory heptapeptide sequence is shown in red and italics.
doi:10.1371/journal.pone.0030452.g001
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underwent autolysis upon standing, resulting in a stable fragment
SERA 5PEc, which leaves a heptapeptide (DNSDNMF) overhang
at the N-terminal of the catalytic domain, which corresponds to
the C-terminal of the prodomain [5]. We wanted to explore the
role of the prodomain and the heptapeptide for the protein and
merozoite egress. SERA5 PD, when expressed in E. coli
accumulated mainly in the soluble fraction, which was purified
by Ni-NTA chromatography followed by gel-permeation chro-
matography. Eluted protein peak (Fig. S1B) was collected, dialyzed
against PBS, pH 7.4 and used for further studies.
SERA5 prodomain inhibited schizont to ring stage
transition
To study the functional relevance of SERA5 PD for the enzyme
domain, we monitored the effect of recombinant SERA5 PD on
cultured asexual blood stages of P. falciparum. Effect of SERA5 PD
on P. falciparum asexual blood stages was studied by addition of
prodomain at ring stage parasites. We observed significant
accumulation of shrunken unruptured schizonts in a dose-
dependent manner after 48 hours post incubation up to nanomolar
concentrations of SERA5 PD (Fig. 2A). A recombinant P. falciparum
protein, high mobility group box protein 2 (HMGB2) prepared in
our laboratory was used as a negative control and E-64, a broad-
spectrum cysteine inhibitor was used as positive control in the above
assay. Parasites treated with the control protein developed with
normal morphology and were mostly present in ring stage after
48 hours (Fig. 2A). Significant populations of unruptured schizonts
were seen in the E-64 treated culture whereas mostly ring stage
parasites were seen in the buffer-treated culture (Fig. 2A).
To ascertain if SERA5 PD specifically blocked the transition
from schizont to ring stages, recombinant protein along with E-64
was incubated with parasite culture at late trophozoite stage. A
dose-dependent accumulation of schizonts was seen in culture
treated with SERA5 PD up to nanomolar concentrations when
compared with buffer-treated culture, which had mostly ring and
trophozoite stage parasites at 24 hours post incubation. E-64-
treated culture was found mostly in schizont stage (Fig. 2B). The
final parasitemia at the time of scoring in both the above
experiments was 4–5%.
Localization of SERA PD inside infected RBCs
Upon incubation of ring stage parasites with fluorescein
isothiocyanate (FITC)-labeled SERA5 PD, FITC-specific fluores-
cence was observed inside schizonts in live culture after 48 hours
of incubation (Fig. 3A), suggesting that the recombinant protein
crossed the erythrocyte and parasitophorous vacuolar membranes.
Parasites were counterstained with DAPI to differentiate between
the uninfected and infected RBCs. Hexahistidine-tagged recom-
binant SERA5 PD was detectable in the Western blot of SERA5
PD-treated parasite lysate after 48 hours of incubation, confirming
that the recombinant protein was able to enter into the parasite
(Fig. 3B).
Interaction of the heptapeptide, DNSDNMF with SERA5 C
Interaction of synthetic peptide, DNSDNMF (Fig. S2) with
SERA5 C was studied by CD spectroscopy and spectrofluorime-
try. Upon addition of the peptide to SERA5 C (5 mM) solution in a
molar ratio of 1:1, significant conformational changes were seen in
the CD spectrum of the protein, demonstrating the interaction of
peptide with protein (Fig. 4A). Intrinsic tryptophan fluorescence
emission spectrum of SERA5 C (1 mM) was recorded upon
excitation at 280 nm and emission between 290 to 500 nm. Upon
addition of peptide (1 mM), quenching in tryptophan fluorescence
emission was seen, confirming the interaction between the peptide
and the protein (Fig. 4B). These results demonstrated that the
heptapeptide binds with the catalytic domain.
Figure 2. Inhibitory effect of SERA5 prodomain on parasite
growth. Panel A: Schizonts were accumulated in a dose-dependent
manner upon treatment of culture with SERA5 PD (referred as PD) at
ring stage. Control P. falciparum protein recombinant HMGB2 had no
effect on parasite growth. E-64 (10 mM) was taken as positive control,
which caused significant accumulation of schizonts. Geimsa-stained
smears of parasite culture were observed by light microscopy after
48 hours of treatment. Data is representative of mean of triplicate
experiments. Error bars represent standard deviation of mean. Panel B:
Schizonts were accumulated in a dose-dependent manner upon
treatment of culture with SERA5 PD (referred as PD) at late trophozoite
stage. E-64 (10 mM) was taken as positive control, which caused
significant accumulation of schizonts. Geimsa-stained smears of parasite
culture were observed by light microscopy after 24 hours of treatment.
Data is representative of mean of triplicate experiments. Error bars
represent standard deviation of mean.
doi:10.1371/journal.pone.0030452.g002
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schizont to ring stage
Incubation of DNSDNMF with parasite culture at the ring
stages of the parasite resulted in accumulation of unruptured
schizonts in a dose-dependent manner when observed after
48 hours of incubation (Figure 5). This effect was similar to
incubation with the prodomain but occurred at ,1000-fold higher
concentrations. Culture treated with E-64 also showed accumu-
lation of unruptured schizonts. To ascertain if the observed effects
were peptide-specific, a control peptide, SIINFEKL (commercially
procured from Techno Concept) was incubated with the culture at
ring stage at 100 mM concentration. Parasites treated with the
control peptide developed normally and were mainly found in ring
stage. The final parasitemia at the time of scoring in the above
experiment was 4–5% (Figure 5).
Discussion
SERA5 is considered a potential drug target against malaria due
to its indispensability for parasite survival [8] and its role in
merozoite egress [11,17]. Inside parasitophorous vacuole, SERA5
undergoes extensive proteolytic maturation by certain proteases. A
serine protease belonging to subtilase clan, PfSUB1 processes
SERA5 precursor into a 47 kDa N-terminal fragment and a
central 56-kDa papain-like protease domain. The 56-kDa
fragment in further processed by an unknown protease into a
50-kDa-fragment (SERA 5PE) [11] which possesses weak
chymotrypsin like activity [5].
The present study was specifically focused on the significance of
SERA5 prodomain (SERA5 PD) and catalytic domain (SERA5
C). Recombinant SERA5 C was found to be proteolytically
inactive on fluorogenic substrates in in vitro assays described for
SERA 5PE [5]. This observed loss of activity might be due to the
absence of the prodomain, which may have chaperone like
function and help in proper folding of the protease domain.
Propeptides are known to have role in proper folding of their
cognate proteases and in most cases they are cleaved upon
maturation of the enzyme [22,23]. In contrast, the prodomain of
SERA5 remains attached to the protease domain and the whole
PE domain is proteolytically active, hence the prodomain allows
Figure 3. Localization of FITC-labeled SERA5 PD in schizont
stage parasites after 48 hour of treatment. Panel A. Culture at
ring stage was treated with 100 nM of FITC-labeled SERA5 PD and
observed after 48 hours after counterstaining with DAPI. FITC
fluorescence is seen in schizont stage parasites but absent in uninfected
RBCs. Panel B. Signals corresponding to recombinant SERA5 PD and
control protein HMGB2 (both with N-terminal hexahistidine tags) were
detected in SERA5 PD- and HMGB2-treated parasite lysates respectively
when probed with anti-hexahistidine antibody after 48 hours of
incubation.
doi:10.1371/journal.pone.0030452.g003
Figure 4. Interaction of heptapeptide, DNSDNMF with SERA5
catalytic domain. Panel A shows the interaction of DNSDNMF with
SERA5 C by CD spectroscopy. The peptide induced significant
conformational change when added with protein in 1:1 molar ratio.
Panel B shows the interaction of DNSDNMF with SERA5 C by
spectrofluorimetry. The peptide induced quenching of the tryptophan
fluorescence upon incubation with protein in 1:1 molar ratio.
doi:10.1371/journal.pone.0030452.g004
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SERA 5PE, in human immunodeficiency virus-1 protease (HIV-1
PR), two b-strands of the prodomain called ‘‘flaps’’ fold on the
active site of the enzyme and hence control the activity of the
protease [24].
Although there are indirect evidences implicating SERA5 in
merozoite egress [11,17], the role of its protease activity is an area
to be explored, particularly given the weak proteolytic activity of
SERA 5PE and lack of information about the physiological
substrates of the protease. Sequence alignment with other
cathepsin L-like cysteine proteases revealed significant differences
with classical proteases. Two other proteases, testin and silicatein,
in which active site cysteine has been substituted with serine, do
not possess proteolytic activity and perform different physiological
functions [25]. Knockout studies of serine type SERAs in
Plasmodium berghei have demonstrated that disruption of P. berghei
SERA1 and 2 did not affect the development of parasites
suggesting some auxiliary role of serine type SERAs (probably
substrate recognition for the redundant cysteine type SERAs) [26].
Based on these findings, some regulatory roles for SERA5 other
than proteolysis can be speculated. However, the exact role played
by this enigmatic protein still remains a mystery.
Incubation of SERA5 prodomain (SERA5 PD) with cultured
parasites at ring (6–8 hours) and mature trophozoite (32–36 hours)
stages significantly delayed the transition of parasites from schizont
to ring stage, which resulted in accumulation of unruptured
schizonts in a dose-dependent manner. We suggest that there may
be other functions for SERA5 prodomain besides regulating
enzyme activity. Prodomains are known to be specific for their
cognate proteases and carry out a variety of functions. Folding of
the prodomain on enzyme active sites is a common phenomenon
that keeps the enzyme in inactive form until certain physiologic
conditions trigger the maturation of the enzyme. Maturation of the
enzyme is accompanied by the proteolytic removal of the
prodomain, which in many cases undergoes degradation by its
cognate protease [27,28]. Besides, inhibiting the active site,
prodomains are also involved in numerous other processes
including chaperone function, trafficking of the enzyme to its
destination and substrate recognition [21,28,29]. Since, biological
proteolytic events carried out by SERA5 are not known, the exact
role played by the prodomain remains unclear. However, if the
proenzyme form is considered active under physiological condi-
tions, we may speculate that the prodomain may help in
recognition and binding of the substrate and the addition of
prodomain to culture may sequester the physiological substrate(s)
from interacting with the enzyme. In a similar study, addition of
recombinant prodomain of Cryptosporidium parvum subtilisin-like
serine protease to parasite culture resulted in inhibition of infection
of HCT-8 cells in vitro in a dose-dependent manner [30].
Earlier, Hodder et al. (2003) have shown that the major autolysis
product of SERA5 proenzyme domain (5PEc) retains an 18-
residue disulfide-bonded cyclic peptide at the C-terminal of the
prodomain which might fold on the active site of the enzyme and
further narrowed down it to the peptide sequence, DNSDNMF at
the C-terminal of the loop, which was suggested to fold on the
active site [5]. Interaction of this heptapeptide with the catalytic
domain was confirmed by CD spectroscopy and fluorimetry,
though the exact mechanism of this interaction is not clear. The
peptide also delayed rupture of schizonts but at approximately
1000-fold higher concentrations of that with SERA5 PD.
Figure 5. Inhibitory effect of heptapeptide, DNSDNMF on parasite growth. Culture was treated with peptide, DNSDNMF and control
peptide, SIINFEKL at ring stage. Geimsa-stained smears were observed after 48 hours of treatment. Accumulation of schizonts was seen at 100 mM
concentration of peptide, DNSDNMF. Control peptide, SIINFEKL did not have any significant effect on culture growth. Data is representative of mean
of triplicate experiments. Error bars represent standard deviation of mean.
doi:10.1371/journal.pone.0030452.g005
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SERA5 in merozoite egress from RBCs [11,17]. These effects of
the prodomain and its derived peptide on parasite growth
demonstrate the importance of the prodomain for the enzyme
domain, but in absence of any information about the physiological
significance of SERA5 proteolytic activity, it still remains an area
to be investigated. Fairlie et al. (2008) have shown that a 14-residue
long disulfide-bonded peptide selected by phage display screening
targets the catalytic domain of SERA5 and delays the rupture of
schizonts in a dose-dependent manner and hence demonstrated
the potential of SERA5 as a drug target and its feasibility to be
targeted by small molecules [31]. Hodder et al. (2009) solved the
crystal structure of the catalytic domain; however, the peptide
could not be co-crystallized with the catalytic domain [32].
Results of this study have also shown that prodomain of SERA5
is crucial for the protein and is inhibitory to merozoite egress. This
finding also confirms the role SERA5 in merozoite egress and
underscores its potential as a drug target. A heptapeptide derived
from the C-terminal of SERA5 PD also had inhibitory effect on
merozoite egress suggesting that peptidomimetic inhibitors based
on the SERA5 prodomain sequences can be developed as future
antimalarials.
Materials and Methods
Preparation of recombinant SERA5 catalytic domain
(SERA5 C) and SERA5 prodomain (SERA5 PD)
SERA5 (PlasmoDB ID: PFB0340c) catalytic domain encoding
region (sera5c) and prodomain encoding region (sera5pd) were PCR
amplified from cDNA of asynchronous P. falciparum 3D7 parasites
by using the primer pair: forward (S5CFw) 59-GGCGCGGAT-
CCGAAAATAATTGTATATCTA ATCTTCAAGTTG-39 and
reverse (S5CRv) 59-GGCCGCTCGAGCTAATTATTCATAG-
GTAAATCAACATTGAATATAAC-39 and forward (S5PDFw)
59-GGCGCGGATCCACAGAAGATGATGATGAAGATGAT-
TATACTG-39 and reverse (S5PDRv), 59-GGCCGCTCGAGC-
TAATCTTTTAATCTGTTACAATATTCTTTATTACA-39 re-
spectively. PCR products were cloned into pGEM-T Easy vector
(Promega) and sequenced by dideoxy chain termination reaction.
After sequencing sera5c and sera5pd were subcloned into
pProExHTb vector (Invitrogen) between BamHI and XhoI sites
with N-terminal hexahistidine tag. SERA5 C and SERA5 PD
were expressed in E.coli BL21(DE3) cells. Expression was induced
with isopropyl b-D-thiogalactopyranoside for 4 hours at 37uC and
cells were harvested by centrifugation.
For purification of SERA5 C, cell pellets were suspended in lysis
buffer (10 mM Tris-HCl, 10 mM EDTA, 100 mM NaCl, 5 mM
benzamidine-HCl, 10 mM DTT pH 8.0). Cells were lysed by
addition of lysozyme and sonication and the lysate was cleared by
centrifugation. The pellet was washed in inclusion body wash
buffer 1 (10 mM Tris-HCl, 10 mM EDTA, 100 mM NaCl, 4 M
urea, 2% Triton X-100, pH 8.0) and inclusion body wash buffer 2
(10 mM Tris-HCl, 1 M NaCl, pH 8.0) respectively, after which
they were suspended in solubilization buffer (20 mM Tris-HCl,
250 mM NaCl, 10 mM imidazole, 6 M guanidine-HCl, pH 8.0)
and stirred at room temperature for 6 hours. Solubilized inclusion
bodies were centrifuged at 10000 rpm for 30 minutes at 4uC and
supernatants were collected. Supernatants were passed through
Ni-NTA agarose beads and washed with 10 column volumes of
each wash buffer 1 (20 mM Tris-HCl, 250 mM NaCl, 6 M Gu-
HCl, pH 8.0) and wash buffer 2 (20 mM Tris-HCl, 250 mM
NaCl, 8 M urea, pH 8.0). Bound protein was eluted with 5
column volumes of 20 mM Tris-HCl, 1 M imidazole, 8 M urea,
20 mM b-mercaptoethanol, pH 8.0. Ni-NTA eluates were
concentrated by Centriprep column of 10-kDa cutoff (Millipore)
and refolded by rapid dilution technique. For refolding, concen-
trated protein (2 mg/ml) was added to the refolding buffer
(20 mM Tris-HCl, 100 mM NaCl, 2 M urea, 1 mM reduced
glutathione, 0.25 mM oxidized glutathione, pH 8.0) in 1:40 ratio
and kept with stirring at 10uC for 48 hours for refolding. Protein
was dialyzed against 50 mM Na2HPO4, 500 mM NaCl, pH 7.5.
For purification of SERA5 PD, cells were lysed in buffer
(50 mM NaH2PO4, 300 mM NaCl, 10 mM imdazole, pH 8.0)
by addition of lysozyme and sonication and the lysate was cleared
by centrifugation. Cleared lysate was passed through Ni-NTA
agarose and then washed extensively with wash buffer (50 mM
NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0). Bound
protein was eluted by step-wise gradient of imidazole in buffers
(50 mM NaH2PO4, 300 mM NaCl, pH 8.0) and analyzed by
SDS-PAGE. Protein was further purified by gel-permeation
chromatography. Fractions containing recombinant protein were
resolved on 16/60 Superdex 75 gel permeation column
(Pharmacia Biotech) in buffer (50 mM Na2HPO4,5 0 0 m M
NaCl, pH 7.5) with a flow rate of 0.5 ml/min and absorbance
was measured at 214 nm. Individual peaks were collected and
analyzed by SDS-PAGE.
Synthesis and purification of peptide, DNSDNMF
Peptide, DNSDNMF (D
560 to F
566 of SERA5 sequence) was
synthesized by solid phase method using Fmoc chemistry at a scale
of 0.2 mM, on Rink Amide MHBA resin (Novabiochem). The
peptide was purified by reversed phase-HPLC, using a semipre-
parative C18 column (Phenomenex) on HPLC system (Shimadzu).
Solvent gradient was made by solvent A (water with 0.1% TFA)
and solvent B (acetonitrile with 0.1% TFA) and the peptide was
eluted by a 1% per minute gradient of solvent B from 5% to 75%
and monitored by absorbance at 214 nm. Purified peptide was
identified by electrospray ionization-mass spectrometry.
Treatment of P. falciparum culture with SERA5 PD
To assess the effect of SERA5 PD on P. falciparum growth,
parasite culture was synchronized by sorbitol treatment. Synchro-
nous culture at ring stage (6–8 hours) at 2% parasitemia was
incubated with SERA5 PD (in PBS, pH 7.4) in 1 mM, 100 nM,
10 nM and 1 nM concentrations (in triplicate) in 96-well flat-
bottomed cell culture plate (NUNC) along with cysteine protease
inhibitor, E-64 at 10 mM concentration (in triplicate) as positive
control. A control protein, P. falciparum high mobility group box 2
protein (HMGB2) (in PBS, pH 7.4) was used as a negative control
at a concentration of 5 mM (in triplicate). After 48 hours of
incubation, percentage of late stage parasites was calculated from
the Geimsa-stained smears of infected RBCs by counting nearly
4000 RBCs. To study the effect of SERA5 PD specifically on
schizont rupture, parasite culture was treated similarly at late
trophozoite stage and Geimsa-stained smears were observed after
24 hours of treatment by counting nearly 4000 RBCs.
Localization of FITC-labeled SERA5 PD in infected RBCs
(iRBCs)
Purified SERA5 PD was incubated with NHS-FITC (Calbio-
chem) in 10-fold molar excess of amino groups in the protein (20
amino groups) and incubated at room temperature with gentle
rocking for 45 minutes. Excess FITC was removed by dialysis in
PBS, pH 7.4. Measuring absorbance at 490 nm against buffer
blank checked labeling of the protein. Parasite culture at ring stage
(2% parasitemia) was incubated with FITC-labeled protein
(100 nM) was incubated at a concentration of with the culture
Inhibitory Potential of PfSERA5 Prodomain
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48 hours. Parasites were counterstained with DAPI and smears of
parasites were observed by fluorescence microscopy for FITC and
DAPI signals. Besides, parasite pellets from cultures treated with
recombinant SERA5 PD (100 nM) and HMGB2 (5 mM) were
purified by saponin lysis and lysed in Laemmli sample buffer.
Lysate was resolved by SDS-PAGE, transferred on nitrocellulose
membrane and probed with horseradish peroxidase anti-hexahis-
tidine antibody. Blot was developed with enhanced chemiluminis-
cence kit (Pierce).
Study of interaction of peptide, DNSDNMF with SERA5 C
Interaction of peptide, DNSDNMF with SERA5 C was
determined by circular dichroism (CD) spectroscopy and spectro-
fluorimetry. To study the interaction by CD spectroscopy, CD
spectra of SERA5 C in PBS, pH 7.4 (5 mM) alone and with 5 mM
peptide were recorded on Jasco spectropolarimeter (model J-810)
at 25uC. Scanning speed was 100 nm/min, band width was 1 nm
and cell volume was 0.4 ml. To study the interaction of
DNSDNMF with SERA5 C by spectrofluorimetry, tryptophan
fluorescence emission spectra of SERA5 C in PBS, pH 7.4 (1 mM)
alone and with 1 mM peptide were recorded on LS 50B
spectrofluorimeter (Perkin Elmer). Parameters for spectrum
measurement were; excitation wavelength: 280 nm, emission
wavelength range: 290–500 nm, scanning speed: 900 nm/min,
excitation slit width: 5 nm, emission slit width: 10 nm, number of
accumulations: 5).
Treatment of P. falciparum culture with peptide,
DNSDNMF
To assess the effect of peptide DNSDNMF on P. falciparum
growth, a synchronous ring stage culture at 2% parasitemia was
incubated with peptide solution in water in 100 mM and 10 mM
concentrations in a 96-well flat-bottomed cell culture plate
(NUNC) (in triplicate) along with E-64 in 10 mM concentration
(in triplicate). A control peptide, SIINFEKL in 100 mM concen-
tration in water (in triplicate) was taken as negative control. After
48 hours of incubation, percentage of late stage parasites were
calculated from the Geimsa-stained smears of infected RBCs by
counting nearly 4000 RBCs.
Supporting Information
Figure S1 Purification of SERA5 catalytic domain and
prodomain. Panel A represents Ni-NTA purified SERA5 C
(marked by an arrow). Panel B represents purification profile of
SERA5 PD by size exclusion chromatography. Position of the
eluted protein peak is marked by an arrow, which was resolved by
SDS-PAGE (inset).
(TIF)
Figure S2 Purification of synthetic peptide, DNSDNMF.
Synthetic peptide, DNSDNMF was purified on semipreparative
RP-HPLC column (Phenomenex). Purified peptide peak is marked
by an arrow (Panel A). Identity of the purified peptide was
confirmed by electrospray ionization-mass spectrometry. Experi-
mental mass of the peptide peak was 841.3611 Da that was close
to the expected mass of 840.85 Da (Panel B).
(TIF)
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